Understanding Premature Ovarian Insufficiency: Observations from Multiple Hospitals
Official title: A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency
Run by Women's Hospital School Of Medicine Zhejiang University · NCT06067529 · Data updated 2026-11-12
This study tests how POI develops and affects health by tracking women with POI across several centers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 10 Years to 65 Years |
| Sex | Women only |
| Enrollment | 1080 (estimated) |
| Sponsor | Women's Hospital School Of Medicine Zhejiang University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Hangzhou, Zhejiang and 1 other locations) |
| Status | Recruiting |
| Started | October 10, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT06067529 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women diagnosed with POI under 40 years of age who are willing to participate and provide biological samples.
✕Probably not a fit
Patients who do not experience changes in POI risk factors or health outcomes may not directly benefit from the results.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a hospital-based, multicenter observational study that follows women with POI over time to describe disease characteristics, risk factors, and health outcomes. It will collect information on lifestyle, environment, and biological samples to observe natural progression and health impacts. The study constructs case-control and prospective cohorts to analyze how POI influences overall health and disease risk, aiming to inform clinical decisions. Participation involves baseline assessment, follow-up visits, and long-term data collection. No experimental interventions are involved.
Why it matters
Potential benefit: If successful, findings could improve understanding of POI risk factors and health effects, potentially guiding diagnosis and management.
How similar studies have gone: Previous observational work has explored POI risk factors and health impact, but comprehensive multi-center prospective data are limited, making this study relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Women with POI 1. Inclusion Criteria 1.1 Age at Diagnosis: Less than 40 years of age. 1.2 Diagnosis of POI: Met one of the following diagnostic criteria based on ESHRE guidelines: Spontaneous POI: Oligomenorrhea or amenorrhea for at least 4 months, combined with elevated FSH levels (\> 25 IU/L) on two occasions at least 4 weeks apart. Iatrogenic POI: Documented history of bilateral oophorectomy, or ovarian failure resulting from chemotherapy or radiotherapy. 1.3 Informed Consent: Willing to participate in the study, provide biological samples, and complete long-term follow-up assessments. 2. Exclusion Criteria 2.1 Current Pregnancy or Lactation: Women who were pregnant or breastfeeding at the time of enrollment. 2.2 Severe Systemic Conditions: Presence of severe somatic or psychiatric diseases (e.g., active malignancy not related to POI, severe heart/renal failure, or cognitive impairment) that would preclude adherence to the study protocol or long-term follow-up. Control 1. Inclusion Criteria: 1.1 Age: 18-50 years. 1.2 Menstrual History: Regular menstrual cycles (21-35 days) for the past 12 months. 1.3 Consent: Willingness to participate, provide biological samples, and provide written informed consent. 2. Exclusion Criteria: 2.1 Physiological Status: Pregnancy, breastfeeding, or clinical perimenopause/postmenopause. 2.2 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies. 2.3 Iatrogenic \& Toxic Factors: Prior ovarian surgery (e.g., cystectomy), chemotherapy, or radiotherapy. 2.4 Systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, or hematological diseases, or malignancy. 2.5 Genetic \& Familial Background: First-degree relatives with POI or early menopause (\< 45 years). Family history of hereditary diseases. 2.6 Medication: Use of hormonal drugs or contraceptives within the last 6 months. Ovarian Surgery group 1. Inclusion Criteria: 1.1 Age: 18-60 years. 1.2 Patients with ovarian surgery: women scheduled to undergo ovarian surgery for gynecological disease. 1.3 Informed Consent: Willing to participate in the study, provide biological samples, and sign the informed consent. 2. Exclusion Criteria: 2.1 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies. 2.2 Medication: Use of hormonal drugs or contraceptives within the last 6 months. 2.3 Genetic or chromosomal abnormalities: Turner syndrome, or other genetic disease. 2.4 Physiological Status: Pregnancy, breastfeeding, or seeking the help of assisted reproductive technology. 2.5 Severe systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, hematological diseases, malignancy, or cognitive impairment. Oophorectomy group 1. Inclusion Criteria: 1.1 Age: 45-65 years. 1.2 Patients with oophorectomy: women scheduled to undergo oophorectomy due to gynecological diseases and met criteria for being menopausal. 1.3 Menopausal status: at least 12 consecutive months of amenorrhea without other medical causes. 1.3 Informed Consent: Willing to participate in the study, provide biological samples, and sign the informed consent. 2. Exclusion Criteria: 2.1 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies. 2.2 Medication: Use of hormonal drugs or contraceptives within the last 6 months. 2.3 Genetic or chromosomal abnormalities: Turner syndrome, or other genetic disease 2.4 Physiological Status: Pregnancy, breastfeeding, or seeking the help of assisted reproductive technology. 2.5 Severe systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, hematological diseases, malignancy, or cognitive impairment.
Where it's running
-
Women's Hospital School of Medicine Zhejiang University
Hangzhou, Zhejiang, China Recruiting -
Women's Hospital School of Medicine Zhejiang University
Hangzhou, Zhejiang, China Not yet recruiting
Study contacts
- Study coordinator: Jianhong Zhou, Doctor of Medicine(M.D.)
- Email: zhoujh1117@zju.edu.cn
- Phone: 86 15990008569
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Autologous Hair Follicle Secretome + PRP for POI
This pilot study tests whether a patient’s own hair follicle secretome combined with their own platelet-rich plasma can improve ovarian function in women with premature ovarian insufficiency.
-
Intravenous hUC-MSCs for POI: Safety, Tolerability and Early Efficacy
We’re testing whether IV human umbilical cord mesenchymal stem cells can be safely given to women under 40 with premature ovarian insufficiency to see if it helps improve ovarian function.
-
Human amniotic mesenchymal stem cell treatment for premature ovarian insufficiency
This trial will test whether an intravenous infusion of human amniotic mesenchymal stem cells combined with standard hormone therapy can help women under 40 with premature ovarian insufficiency.
-
Hormone replacement for adolescents with premature ovarian insufficiency
This study will test estrogen patches plus progesterone in girls and young women aged 11–19 with premature ovarian insufficiency to see if hormone replacement improves bone density, metabolic markers, muscle strength, and cardiovascular health.
-
Using Platelet-rich Plasma to Improve Female Fertility
This study is testing whether injections of platelet-rich plasma can help improve fertility in women dealing with issues like poor ovarian response and repeated implantation failure.
-
Using fat-derived cells to treat premature ovarian insufficiency
This study is testing if using fat-derived cells can help improve pregnancy chances for women with premature ovarian insufficiency compared to standard IVF treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.